TOM (psychedelic)
TOM (psychedelic) is a class of psychedelic drugs that were first synthesized in the late 20th century. The name "TOM" is an acronym for "2,5-dimethoxy-4-alkylthiophenethylamine." These substances are part of the larger family of phenethylamine compounds, which also includes other psychedelic drugs such as mescaline and 2C-B.
History[edit | edit source]
The TOM class of psychedelics was first synthesized by Alexander Shulgin, a renowned chemist and psychopharmacologist. Shulgin's work in the field of psychedelic research led to the discovery and synthesis of many new psychedelic compounds, including the TOMs. His findings were published in the book PiHKAL (Phenethylamines I Have Known And Loved), which has since become a seminal text in the field of psychedelic research.
Chemistry[edit | edit source]
TOM psychedelics are phenethylamine derivatives, meaning they are structurally related to naturally occurring compounds such as dopamine and adrenaline. The defining feature of the TOM class is the presence of a sulfur atom in the 4-position of the phenethylamine molecule, which is thought to contribute to their unique psychedelic effects.
Pharmacology[edit | edit source]
Like other psychedelic drugs, TOMs are thought to exert their effects primarily through interaction with the serotonin system in the brain. They are believed to act as agonists at the 5-HT2A receptor, which is known to play a key role in the regulation of mood, perception, and cognition.
Effects[edit | edit source]
The effects of TOM psychedelics can vary widely depending on the specific compound and the dose used. However, common effects reported by users include visual hallucinations, altered perception of time, enhanced introspection, and a sense of spiritual or mystical experience. As with all psychedelic drugs, the effects can be influenced by a variety of factors including the user's mindset, environment, and individual brain chemistry.
Legal Status[edit | edit source]
The legal status of TOM psychedelics varies by country and by specific compound. In many jurisdictions, they are classified as controlled substances, making their manufacture, sale, and possession illegal. However, there is ongoing debate and research into the potential therapeutic uses of these and other psychedelic substances.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD